Studies related to Obsession/compulsion and Saffron

Affron ®, A Standardised Extract From Saffron (Crocus Sativus L.) For The Treatment Of Youth Anxiety And Depressive Symptoms: A Randomised, Double-blind, Placebo-controlled Study

Effect Decrease
Values Mean and SE. RCADS score. Children: before 6.10 (0.43), after 4.00 (0.52). Saffron: before 5.20 (0.49), after 2.39 (0.51). Parents: before 3.70 (0.53), after 2.38 (0.37). Saffron: before 2.95 (0.38), after 1.08 (0.24).
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 80
Sex Both Genders
Notes for this study:
In a randomized, double-blind, placebo-controlled trial, 80 children aged 12 to 16 with mild-to-moderate anxiety or depression took 14 mg of saffron extract ("derived from the stigmas of Crocus sativus L.
and standardized to contain >3.5% Lepticrosalides® a measure of bioactive compounds present in saffron, including safranal and crocin isomers") twice daily for 8 weeks.

There was a greater reduction in separation anxiety, social phobia, and depression rated by children. The differences weren't statistically significant when rated by parents, however. There weren't statistically significant differences for panic, obsessions/compulsions, or generalized anxiety, though saffron seems to reduce them more than placebo.

The trial was preregistered: ACTRN12617000155392